Govorestat
An investigational treatment for Charcot-Marie-Tooth Disease.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Govorestat wherever you encounter it, plus the key facts at a glance.
- Generic name
- Govorestat
- Development code
- AT-007
- Drug class
- Aldose reductase inhibitor (oral small molecule)
- Manufacturer
- Cycle Pharmaceuticals (Applied Therapeutics)
- How it's taken
- Taken by mouth as an oral capsule, once daily.
An investigational oral aldose reductase inhibitor in development for CMT-SORD, a recessive form of Charcot-Marie-Tooth disease caused by mutations in the SORD gene.
- In its Phase 2/3 INSPIRE trial, Applied Therapeutics reported in May 2025 that govorestat did not beat placebo on the main goal, a timed 10-meter walk or run, though it lowered blood sorbitol and improved a patient-reported score.
- No FDA application for CMT-SORD has been announced.
- The same molecule was studied in classic galactosemia, where the FDA issued a Complete Response Letter in November 2024.
We'll email you when the FDA acts on Govorestat and when new trials for Charcot-Marie-Tooth Disease open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Govorestat fits
Investigational, not yet approved.
- If approved, would be the first FDA-approved disease-modifying therapy for any CMT subtype.
- Only relevant for patients with biallelic SORD mutations confirmed on genetic testing, so confirming subtype with a broad gene panel is the first step.
How Govorestat works
CMT-SORD is caused by changes (mutations) in both copies of a gene called SORD. The SORD gene normally produces an enzyme that helps clear sorbitol, a sugar-alcohol that the body makes from glucose. When SORD is broken, sorbitol cannot be cleared properly. It builds up in peripheral nerve cells and damages them, causing the slowly progressive weakness and sensory loss patients experience.
Govorestat works one step further upstream. It blocks aldose reductase, the enzyme that converts glucose into sorbitol in the first place. By stopping the build-up at the source, govorestat lowers the toxic sorbitol levels that drive the nerve damage. Treatment is taken as a once-daily pill, which makes it different from the AAV gene therapies being tested for other CMT subtypes (those require injections into the spinal fluid).
INSPIRE did not meet its main walking goal, and after a 2025 meeting the FDA listed open questions before any application, including whether sorbitol levels can stand in for clinical benefit. If govorestat were ever approved, it would be the first drug approved specifically for CMT-SORD.
Clinical trial results
[INSPIRE (NCT05397665)](https://clinicaltrials.gov/study/NCT05397665) was the pivotal Phase 2/3 trial of govorestat in patients with confirmed CMT-SORD (biallelic SORD mutations). It enrolled 56 people, randomly assigned 2 to 1 to govorestat or placebo. Applied Therapeutics reported on May 18, 2025 that the main goal, change in a timed 10-meter walk or run at 12 months, was not met (p=0.457).
The CMT Health Index, a patient-reported measure of daily life, improved compared with placebo (p=0.039), and blood sorbitol fell (p<0.001). These 12-month results covered 49 people who could be evaluated. ClinicalTrials.gov lists the study as completed on June 1, 2026, and the results have not been posted there yet. A separate confirmatory Phase 3 study (NCT07191912) was withdrawn before enrolling anyone because the sponsor decided not to start it.
Main registered trial: NCT05397665 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
Applied Therapeutics reported that govorestat was generally well tolerated in the INSPIRE trial, with side effects about as common as on placebo, and it did not list which side effects were most common. In a trial in children with classic galactosemia, stomach and gut problems were reported most often, with vomiting in 48.4% of children on govorestat against 31.3% on placebo and diarrhea in 25.8% against 12.5%.
Colds and rises in liver enzymes were also more common on govorestat, and that trial reported no serious or severe side effects. Adults with CMT-SORD may not have the same experience as children with galactosemia.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Govorestat
Taken by mouth as an oral capsule, once daily. There is no approved dose for CMT-SORD.
Development history
Govorestat (then called AT-007) was originally developed by Applied Therapeutics for classic galactosemia. After researchers identified that mutations in SORD cause a treatable form of CMT through the same sorbitol-buildup mechanism, Applied Therapeutics expanded the development program to CMT-SORD. The company hit FDA setbacks in galactosemia (a Complete Response Letter on November 27, 2024) and in November 2025 the company said it had not settled on a path to an FDA application for CMT-SORD.
Cycle Pharmaceuticals completed its acquisition of Applied Therapeutics in February 2026.
Explore Charcot-Marie-Tooth Disease trials
Other Charcot-Marie-Tooth Disease treatments
Common questions about Govorestat
▸What is Govorestat?
An investigational oral aldose reductase inhibitor in development for CMT-SORD, a recessive form of Charcot-Marie-Tooth disease caused by mutations in the SORD gene. In its Phase 2/3 INSPIRE trial, Applied Therapeutics reported in May 2025 that govorestat did not beat placebo on the main goal, a timed 10-meter walk or run, though it lowered blood sorbitol and improved a patient-reported score. No FDA application for CMT-SORD has been announced. The same molecule was studied in classic galactosemia, where the FDA issued a Complete Response Letter in November 2024.
▸How does Govorestat work?
CMT-SORD is caused by changes (mutations) in both copies of a gene called SORD. The SORD gene normally produces an enzyme that helps clear sorbitol, a sugar-alcohol that the body makes from glucose. When SORD is broken, sorbitol cannot be cleared properly. It builds up in peripheral nerve cells and damages them, causing the slowly progressive weakness and sensory loss patients experience.
Govorestat works one step further upstream. It blocks aldose reductase, the enzyme that converts glucose into sorbitol in the first place. By stopping the build-up at the source, govorestat lowers the toxic sorbitol levels that drive the nerve damage. Treatment is taken as a once-daily pill, which makes it different from the AAV gene therapies being tested for other CMT subtypes (those require injections into the spinal fluid).
INSPIRE did not meet its main walking goal, and after a 2025 meeting the FDA listed open questions before any application, including whether sorbitol levels can stand in for clinical benefit. If govorestat were ever approved, it would be the first drug approved specifically for CMT-SORD.
▸What are the side effects of Govorestat?
Applied Therapeutics reported that govorestat was generally well tolerated in the INSPIRE trial, with side effects about as common as on placebo, and it did not list which side effects were most common. In a trial in children with classic galactosemia, stomach and gut problems were reported most often, with vomiting in 48.4% of children on govorestat against 31.3% on placebo and diarrhea in 25.8% against 12.5%. Colds and rises in liver enzymes were also more common on govorestat, and that trial reported no serious or severe side effects. Adults with CMT-SORD may not have the same experience as children with galactosemia.
▸How is Govorestat taken?
Taken by mouth as an oral capsule, once daily. There is no approved dose for CMT-SORD.
▸Is Govorestat FDA approved?
Govorestat is currently in phase 3 clinical trials for Charcot-Marie-Tooth Disease. It has not yet received FDA approval.
▸What is govorestat used for?
Govorestat (AT-007) is an investigational oral aldose reductase inhibitor in development for CMT-SORD, a recessive form of Charcot-Marie-Tooth disease caused by mutations in both copies of the SORD gene. It blocks the enzyme that converts glucose into sorbitol, lowering the toxic sorbitol build-up that damages peripheral nerves. It is only relevant for patients with biallelic SORD mutations confirmed on genetic testing. [1]
▸Is govorestat FDA approved?
No, govorestat is not FDA-approved. Its Phase 2/3 INSPIRE trial in CMT-SORD did not meet its main goal, a timed walking test, according to Applied Therapeutics in May 2025, and no FDA application for CMT-SORD has been announced. The same molecule was studied in classic galactosemia, where the FDA issued a Complete Response Letter on November 27, 2024. [1][4][6]
▸What is the govorestat INSPIRE trial?
INSPIRE (NCT05397665) was the pivotal Phase 2/3 trial of govorestat versus placebo in patients with confirmed CMT-SORD, measuring changes in nerve function and patient-reported function over time. Applied Therapeutics reported in May 2025 that the main goal, a timed 10-meter walk or run at 12 months, was not met, while a patient-reported score improved and blood sorbitol fell. ClinicalTrials.gov lists the study as completed on June 1, 2026, without posted results, and a separate confirmatory Phase 3 study was withdrawn before enrolling anyone. [1][4][2]
▸How is govorestat taken and what are its side effects?
Govorestat is taken by mouth as a once-daily oral capsule, and there is no approved dose for CMT-SORD. Applied Therapeutics reported it was generally well tolerated in the INSPIRE trial for CMT-SORD. In a galactosemia trial in children, vomiting and diarrhea were the most common side effects, and none were serious or severe. People with CMT-SORD may have a different experience. [1][3]
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Applied Therapeutics (GlobeNewswire) · 2025-05-18. Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD. https://www.globenewswire.com/news-release/2025/05/18/3083535/0/en/Applied-Therapeutics-Presents-Full-12-Month-Clinical-Results-and-New-Topline-Data-from-INSPIRE-Phase-2-3-Trial-of-Govorestat-in-CMT-SORD-in-Late-Breaking-Oral-Presentation-at-the-P.html
- U.S. National Library of Medicine, ClinicalTrials.gov. Confirmatory Phase 3 study of govorestat in CMT-SORD (withdrawn). https://clinicaltrials.gov/study/NCT07191912
- Journal of Clinical Pharmacology · 2024. Govorestat in children with classic galactosemia (ACTION-Galactosemia Kids). https://pmc.ncbi.nlm.nih.gov/articles/PMC12034909/
- U.S. National Library of Medicine, ClinicalTrials.gov. Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency. https://clinicaltrials.gov/study/NCT05397665
- Hereditary Neuropathy Foundation. Charcot-Marie-Tooth Disease, Clinical Trials. https://www.hnf-cure.org/our-impact/clinical-trials/
- Applied Therapeutics · 2024-11-27. Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia. https://www.globenewswire.com/news-release/2024/11/27/2988438/0/en/Applied-Therapeutics-Receives-Complete-Response-Letter-from-U-S-FDA-Regarding-New-Drug-Application-for-Govorestat-for-Classic-Galactosemia.html
- Cycle Pharmaceuticals · 2026-02-03. Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics. https://cyclepharma.com/news/acquisition-of-applied-therapeutics/